OSL
Oncosil Medical Ltd
$0.8400
▼ -2.33%
Market cap
$31M
Turnover
$30,753
Last price
$0.8400
Day change
-2.33%
Announcements
14
Range, past year
Open 1.660 · Low 0.002 · Now 0.840 · High 2.090
Open OSL in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
OSL momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-29.
Momentum quality
34/100
Wyckoff phase
Accumulation48d
Trend stage
Distribution
1 Day
-2.3%
1 Week
-10.6%
1 Month
-27.0%
1 Year
-49.7%
RSI
36
Avg daily range
8.7%
Oncosil Medical Ltd scores 34 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Distribution.
On the Wyckoff cycle it sits in Accumulation, where it has been for 48 trading days. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -46.6%
- High volatility (ATR 8.7%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
OSL announcements
Recent price-sensitive releases.
- 2026-09-09 Australian Manufacturing Facility Achieves ISO 13485 Progress Report
- 2026-09-07 OSL Secures $5.6 million from Major Institutional Investors Placement
- 2026-08-28 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-17 OncoSil Receives FDA Approval for Distal Cholangiocarcinoma Web Cast | Progress Report
- 2026-07-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-13 OncoSil Medical Completes Manufacturing Validation
- 2026-07-03 OncoSil Medical Files for FDA Approval
More Health Care stocks
Most traded in the same sector.